vs

Side-by-side financial comparison of FRANKLIN STREET PROPERTIES CORP (FSP) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

FRANKLIN STREET PROPERTIES CORP is the larger business by last-quarter revenue ($26.0M vs $19.6M, roughly 1.3× STANDARD BIOTOOLS INC.). FRANKLIN STREET PROPERTIES CORP runs the higher net margin — -28.1% vs -177.4%, a 149.3% gap on every dollar of revenue. On growth, FRANKLIN STREET PROPERTIES CORP posted the faster year-over-year revenue change (-8.2% vs -11.5%). FRANKLIN STREET PROPERTIES CORP produced more free cash flow last quarter ($-12.7M vs $-23.1M). Over the past eight quarters, FRANKLIN STREET PROPERTIES CORP's revenue compounded faster (-8.7% CAGR vs -12.2%).

Franklin Street Properties Corp is a Massachusetts-based real estate investment trust (REIT) in the United States. It primarily invests in, owns, and operates high-quality office properties across major U.S. metropolitan markets, serving corporate tenants across various industry segments, and delivers stable long-term returns via rental income and strategic asset management.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

FSP vs LAB — Head-to-Head

Bigger by revenue
FSP
FSP
1.3× larger
FSP
$26.0M
$19.6M
LAB
Growing faster (revenue YoY)
FSP
FSP
+3.2% gap
FSP
-8.2%
-11.5%
LAB
Higher net margin
FSP
FSP
149.3% more per $
FSP
-28.1%
-177.4%
LAB
More free cash flow
FSP
FSP
$10.4M more FCF
FSP
$-12.7M
$-23.1M
LAB
Faster 2-yr revenue CAGR
FSP
FSP
Annualised
FSP
-8.7%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FSP
FSP
LAB
LAB
Revenue
$26.0M
$19.6M
Net Profit
$-7.3M
$-34.7M
Gross Margin
59.4%
48.5%
Operating Margin
-27.9%
-168.5%
Net Margin
-28.1%
-177.4%
Revenue YoY
-8.2%
-11.5%
Net Profit YoY
14.1%
-28.8%
EPS (diluted)
$-0.06
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FSP
FSP
LAB
LAB
Q4 25
$26.0M
Q3 25
$27.3M
$19.6M
Q2 25
$26.7M
$21.8M
Q1 25
$27.1M
$40.8M
Q4 24
$28.4M
Q3 24
$29.7M
$22.1M
Q2 24
$30.8M
$22.5M
Q1 24
$31.2M
$45.5M
Net Profit
FSP
FSP
LAB
LAB
Q4 25
$-7.3M
Q3 25
$-8.3M
$-34.7M
Q2 25
$-7.9M
$-33.5M
Q1 25
$-21.4M
$-26.0M
Q4 24
$-8.5M
Q3 24
$-15.6M
$-26.9M
Q2 24
$-21.0M
$-45.7M
Q1 24
$-7.6M
$-32.2M
Gross Margin
FSP
FSP
LAB
LAB
Q4 25
59.4%
Q3 25
60.9%
48.5%
Q2 25
59.9%
48.8%
Q1 25
62.8%
48.4%
Q4 24
59.7%
Q3 24
61.0%
54.9%
Q2 24
64.2%
46.1%
Q1 24
64.7%
53.1%
Operating Margin
FSP
FSP
LAB
LAB
Q4 25
-27.9%
Q3 25
-30.5%
-168.5%
Q2 25
-29.2%
-118.1%
Q1 25
-78.9%
-80.8%
Q4 24
-29.9%
Q3 24
-52.4%
-120.9%
Q2 24
-68.0%
-134.5%
Q1 24
-24.0%
-132.2%
Net Margin
FSP
FSP
LAB
LAB
Q4 25
-28.1%
Q3 25
-30.5%
-177.4%
Q2 25
-29.5%
-153.7%
Q1 25
-79.1%
-63.8%
Q4 24
-30.0%
Q3 24
-52.6%
-122.0%
Q2 24
-68.2%
-203.3%
Q1 24
-24.2%
-70.6%
EPS (diluted)
FSP
FSP
LAB
LAB
Q4 25
$-0.06
Q3 25
$-0.08
$-0.09
Q2 25
$-0.08
$-0.09
Q1 25
$-0.21
$-0.07
Q4 24
$-0.09
Q3 24
$-0.15
$-0.07
Q2 24
$-0.20
$-0.12
Q1 24
$-0.07
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FSP
FSP
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$30.6M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$607.0M
$399.7M
Total Assets
$892.9M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FSP
FSP
LAB
LAB
Q4 25
$30.6M
Q3 25
$31.4M
$129.4M
Q2 25
$29.4M
$158.6M
Q1 25
$30.2M
$150.9M
Q4 24
$41.1M
Q3 24
$40.9M
$210.6M
Q2 24
$30.2M
$269.8M
Q1 24
$34.2M
$287.1M
Total Debt
FSP
FSP
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
FSP
FSP
LAB
LAB
Q4 25
$607.0M
Q3 25
$615.3M
$399.7M
Q2 25
$624.7M
$424.5M
Q1 25
$633.4M
$454.6M
Q4 24
$655.9M
Q3 24
$665.4M
$489.3M
Q2 24
$682.1M
$510.3M
Q1 24
$703.9M
$577.3M
Total Assets
FSP
FSP
LAB
LAB
Q4 25
$892.9M
Q3 25
$901.0M
$539.6M
Q2 25
$903.2M
$557.0M
Q1 25
$916.4M
$579.6M
Q4 24
$946.9M
Q3 24
$981.5M
$681.5M
Q2 24
$1.0B
$708.7M
Q1 24
$1.0B
$777.7M
Debt / Equity
FSP
FSP
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FSP
FSP
LAB
LAB
Operating Cash FlowLast quarter
$3.8M
$-22.2M
Free Cash FlowOCF − Capex
$-12.7M
$-23.1M
FCF MarginFCF / Revenue
-48.6%
-118.1%
Capex IntensityCapex / Revenue
63.0%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-25.3M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FSP
FSP
LAB
LAB
Q4 25
$3.8M
Q3 25
$8.3M
$-22.2M
Q2 25
$-2.9M
$-20.7M
Q1 25
$-5.5M
$-30.3M
Q4 24
$9.0M
Q3 24
$14.5M
$-27.9M
Q2 24
$-648.0K
$-39.0M
Q1 24
$-7.1M
$-62.5M
Free Cash Flow
FSP
FSP
LAB
LAB
Q4 25
$-12.7M
Q3 25
$3.0M
$-23.1M
Q2 25
$-5.7M
$-22.6M
Q1 25
$-9.9M
$-35.3M
Q4 24
$-16.2M
Q3 24
$8.6M
$-30.1M
Q2 24
$-5.1M
$-41.0M
Q1 24
$-15.8M
$-63.3M
FCF Margin
FSP
FSP
LAB
LAB
Q4 25
-48.6%
Q3 25
11.0%
-118.1%
Q2 25
-21.5%
-103.6%
Q1 25
-36.7%
-86.6%
Q4 24
-57.2%
Q3 24
29.1%
-136.4%
Q2 24
-16.7%
-182.2%
Q1 24
-50.8%
-138.9%
Capex Intensity
FSP
FSP
LAB
LAB
Q4 25
63.0%
Q3 25
19.4%
4.5%
Q2 25
10.7%
8.7%
Q1 25
16.4%
12.4%
Q4 24
88.9%
Q3 24
19.6%
10.2%
Q2 24
14.6%
8.6%
Q1 24
28.1%
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FSP
FSP

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons